Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)23.51K

Market Cap

¥8.97B

Enterprise Value¥8.09B

Total Cash (Recent Filing)¥903.75M

Total Debt (Recent Filing)¥196.94M

Price to Earnings (P/E)27.3

Beta0.90

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)27.81

Shares Outstanding9,314,590

10 Day Avg. Volume28,690

30 Day Avg. Volume23,506

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Conservative Balance Sheet / Low LeverageA very low debt-to-equity ratio and rising equity provide durable financial flexibility: the company can fund R&D, inventory and working capital without heavy refinancing, withstand demand shocks better, and pursue opportunistic investments or partnerships without adding leverage pressure.

Rebounded Cash Generation And Strong FCFSustained positive operating and free cash flow in the latest year indicates the business now converts earnings into usable cash. This supports durable self-funding for capex, working capital and shareholder returns, lowering dependence on external financing over the medium term.

Robust Margins And Profitability TurnaroundHigh gross and operating margins plus a meaningful ROE reflect strong unit economics and pricing power in its niche reagents/assay market. If margins persist, the company can sustain investment in product development and capture recurring consumable revenue with attractive profitability.

Bears Say

Historic Earnings Volatility And Recent Deep LossesA sharp turnaround is valuable, but the prior multi-year losses show the business has experienced structural or demand challenges. This raises the risk that revenue or margin setbacks could reverse profits, making long-term sustainability of current earnings uncertain until multi-year stability is proven.

Inconsistent Cash-flow HistoryAlthough FCF is strong in 2026, prior years of negative or weak cash flow indicate volatility in cash conversion. Irregular cash generation can limit reliable reinvestment, constrain dividends or M&A flexibility, and increase funding risk if operational performance slips again.

Small Scale And Narrow Product FocusA small workforce and concentration in reagent/assay products suggest limited scale and product diversification. This can amplify operational risk, reduce pricing leverage with large customers, and slow expansion into adjacent markets, making growth more sensitive to single-market dynamics.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥8.97B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Aug 06, 2026 which is in 35 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥8.68 earnings per share for the quarter, beating the consensus estimate of N/A by ¥8.68.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥7.441 which represents an annual dividend yield of N/A. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥8.68 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.601%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.